Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.37
$0.06(2.53%)
At close: 4:00 PM EDT
$2.37
$0.06(2.53%)
Day’s Range― - ―
52-Week Range$1.52 - $3.19
Previous CloseN/A
Volume129.84K
Average Volume (3M)607.22K
Market Cap
$191.76M
Enterprise Value$160.20
Total Cash (Recent Filing)$27.42M
Total Debt (Recent Filing)$9.21M
Price to Earnings (P/E)9.9
Beta0.72
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume513,750
30 Day Avg. Volume607,216
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside406.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$78.30M
Bulls Say, Bears Say
Bulls Say
Elfabrio Commercial And Regulatory ExpansionBroader approval and less frequent dosing can reduce treatment burden and improve adoption in Fabry disease. Continued partner-led commercialization also expands reach without requiring Protalix to build a large direct sales infrastructure.
Improved Profitability And Cash GenerationThe shift to positive earnings, strong margins and positive free cash flow indicates that commercial operations can fund a meaningful portion of development. This improves resilience and reduces dependence on external financing.
Debt-free Balance Sheet Supports ExecutionHigh liquidity and no debt or warrants give Protalix flexibility to support manufacturing, regulatory work and pipeline development. The absence of scheduled debt obligations also lowers refinancing risk while products and candidates mature.
Bears Say
Partner Concentration And Lumpy RevenueReliance on Chiesi and variable ordering can make reported revenue difficult to forecast, even when underlying demand is healthy. Concentration also leaves Protalix exposed to a partner's inventory decisions and commercial execution.
Profitability Includes Non-recurring DriversThe milestone is not a recurring sales stream, and the R&D benefit may not fully offset future cost increases. Consequently, current earnings and margins may overstate the sustainable profitability of the underlying business.
PRX-115 Clinical And Immunogenicity UncertaintyA high antibody rate and unresolved dosing trade-offs could limit efficacy, tolerability or dosing convenience for PRX-115. These issues may delay development, increase trial complexity and reduce the pipeline's eventual commercial value.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.52 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $191.76M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 84 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.06.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.02.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 7.819%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (406.33% Upside)
$12.00 (406.33% Upside)
Blogger Sentiment
Neutral
PLX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.49%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(406.33% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.87% Insiders
2.82% Mutual Funds
1.04% Other Institutional Investors
87.02% Public Companies and
Individual Investors